Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses treatment approaches for multiple myeloma (MM) in Europe, drawing focus on the important role of monoclonal antibodies (mAbs). Dr Cerchione first discusses the role of daratumumab in the treatment of transplant-eligible and transplant-ineligible patients, and then goes on to emphasize the value of measurable residual disease (MRD) in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть